Arlene A Forastiere1, Randal S Weber2, Andy Trotti2. 1. Arlene A. Forastiere, Johns Hopkins University and Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Randal S. Weber, The University of Texas MD Anderson Cancer Center, Houston, TX; and Andy Trotti, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. af@jhmi.edu. 2. Arlene A. Forastiere, Johns Hopkins University and Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD; Randal S. Weber, The University of Texas MD Anderson Cancer Center, Houston, TX; and Andy Trotti, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Abstract
PURPOSE: To provide a review of the clinical data, controversies, and limitations that underpin current recommendations for approaches to larynx preservation for locally advanced larynx cancer requiring total laryngectomy. METHODS: The key findings from pivotal randomized controlled trials are discussed, including quality of life, late effects, and function assessments. Trials investigating taxane inclusion in induction chemotherapy and trials of epidermal growth factor receptor inhibition for radiosensitization are put into perspective for larynx cancer. Controversies in the management of T4 primaries and the opportunities for conservation laryngeal surgery are reviewed. RESULTS: There are data from clinical trials to support induction chemotherapy, followed by radiotherapy (preferred approach in Europe) and concomitant cisplatin plus radiotherapy (preferred in North America) for nonsurgical preservation of the larynx. Treatment intensification by a sequential approach of induction, followed by concomitant treatment, is investigational. Transoral laryngeal microsurgery and transoral robotic partial laryngectomy have application in selected patients. CONCLUSION: The management of locally advanced larynx cancer is challenging and requires an experienced multidisciplinary team for initial evaluation, response assessment, and support during and after treatment to achieve optimal function, quality of life, and overall survival. Patient expectations, in addition to tumor extent, pretreatment laryngeal function, and coexisting chronic disease, are critical factors in selecting surgical or nonsurgical primary treatment.
PURPOSE: To provide a review of the clinical data, controversies, and limitations that underpin current recommendations for approaches to larynx preservation for locally advanced larynx cancer requiring total laryngectomy. METHODS: The key findings from pivotal randomized controlled trials are discussed, including quality of life, late effects, and function assessments. Trials investigating taxane inclusion in induction chemotherapy and trials of epidermal growth factor receptor inhibition for radiosensitization are put into perspective for larynx cancer. Controversies in the management of T4 primaries and the opportunities for conservation laryngeal surgery are reviewed. RESULTS: There are data from clinical trials to support induction chemotherapy, followed by radiotherapy (preferred approach in Europe) and concomitant cisplatin plus radiotherapy (preferred in North America) for nonsurgical preservation of the larynx. Treatment intensification by a sequential approach of induction, followed by concomitant treatment, is investigational. Transoral laryngeal microsurgery and transoral robotic partial laryngectomy have application in selected patients. CONCLUSION: The management of locally advanced larynx cancer is challenging and requires an experienced multidisciplinary team for initial evaluation, response assessment, and support during and after treatment to achieve optimal function, quality of life, and overall survival. Patient expectations, in addition to tumor extent, pretreatment laryngeal function, and coexisting chronic disease, are critical factors in selecting surgical or nonsurgical primary treatment.
Authors: C R Bradford; G T Wolf; T E Carey; S Zhu; T F Beals; J M Truelson; K D McClatchey; S G Fisher Journal: Otolaryngol Head Neck Surg Date: 1999-11 Impact factor: 3.497
Authors: Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner Journal: Lancet Oncol Date: 2011-01-11 Impact factor: 41.316
Authors: M Merlano; V Vitale; R Rosso; M Benasso; R Corvò; M Cavallari; G Sanguineti; A Bacigalupo; F Badellino; G Margarino Journal: N Engl J Med Date: 1992-10-15 Impact factor: 91.245
Authors: Michael L Hinni; John R Salassa; David G Grant; Bruce W Pearson; Richard E Hayden; Alexios Martin; Hans Christiansen; Bruce H Haughey; Brian Nussenbaum; Wolfgang Steiner Journal: Arch Otolaryngol Head Neck Surg Date: 2007-12
Authors: Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-04-01 Impact factor: 6.223
Authors: Joshua D Smith; Andrew C Birkeland; Andrew J Rosko; Rebecca C Hoesli; Susan K Foltin; Paul Swiecicki; Michelle Mierzwa; Steven B Chinn; Andrew G Shuman; Kelly M Malloy; Keith A Casper; Scott A McLean; Gregory T Wolf; Carol R Bradford; Mark E Prince; John Chad Brenner; Matthew E Spector Journal: Head Neck Date: 2018-12-12 Impact factor: 3.147
Authors: A Andreano; M Ansarin; D Alterio; R Bruschini; M G Valsecchi; A G Russo Journal: Acta Otorhinolaryngol Ital Date: 2018-02 Impact factor: 2.124
Authors: Connor W Hoban; Lauren J Beesley; Emily L Bellile; Yilun Sun; Matthew E Spector; Gregory T Wolf; Jeremy M G Taylor; Andrew G Shuman Journal: Cancer Date: 2017-11-07 Impact factor: 6.860
Authors: D Alterio; P Franco; G Numico; L Licitra; M Cossu Rocca; A Ferrari; C Pinto; E G Russi; U Ricardi; B A Jereczek Fossa Journal: Med Oncol Date: 2016-06-11 Impact factor: 3.064